3 Innovation Stocks With Parabolic Upside Potential
These three growth stocks might be deeply undervalued.
1 Small-Cap Biotech Stock Poised for a Breakout
This developmental biotech is nearing a key inflection point.
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday - Alerus Financial ( NASDAQ:ALRS ) , Abercrombie & Fitch ( NYSE:ANF )
U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Monday. Shares of Alerus Financial Corporation ALRS rose sharply during Monday's session following better-than-expected quarterly results.
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Arrowhead Pharma ( NASDAQ:ARWR ) , Abivax ( NASDAQ:ABVX )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of GE Vernova Inc. GEV rose sharply during Wednesday's session after the company posted better-than-expected second-quarter 2025 earnings and raised its full-year guidance.
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
SAN DIEGO, July 22, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ( Nasdaq: ATYR ) ( "aTyr" or the "Company" ) , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the last ...
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, July 22, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc.
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
SAN DIEGO, June 26, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ( Nasdaq: ATYR ) ( "aTyr" or the "Company" ) , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the ...
aTyr Pharma to Present at Upcoming Investor Conferences
SAN DIEGO, May 20, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ( Nasdaq: ATYR ) , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society ( ATS ) 2025 International Conference - aTyr Pharma ( NASDAQ:ATYR )
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population.
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis - aTyr Pharma ( NASDAQ:ATYR )
Preclinical data demonstrate ATYR0101's unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society ( ATS ) 2025 Respiratory Innovation Summit. SAN DIEGO, May 14, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc.
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update - aTyr Pharma ( NASDAQ:ATYR )
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be ...
aTyr Pharma to Participate in April Investor Conferences - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, April 03, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ATYR, a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming ...
Is aTyr Pharma ( ATYR ) Stock Outpacing Its Medical Peers This Year?
Here is how Atyr Pharma (ATYR) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update - aTyr Pharma ( NASDAQ:ATYR )
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile.
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile. Company to host conference call and webcast today, March 13th ...
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, March 06, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc.
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ATYR, a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - enGene Holdings ( NASDAQ:ENGN ) , aTyr Pharma ( NASDAQ:ATYR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society ( ATS ) 2025 International Conference
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. topline data from the study expected in the third quarter of ...
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society ( ATS ) 2025 International Conference - aTyr Pharma ( NASDAQ:ATYR )
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025 Current epidemiology and treatment practices for pulmonary sarcoidosis in the U.S. based on ...
This Toast Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - aTyr Pharma ( NASDAQ:ATYR ) , Nano X Imaging ( NASDAQ:NNOX )
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Piper Sandler analyst Brent Bracelin initiated coverage on ServiceTitan, Inc.
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ATYR, a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ATYR ( "aTyr" or the "Company" ) , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric ...
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update - aTyr Pharma ( NASDAQ:ATYR )
Enrollment completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data expected in the third quarter of 2025. Publication in European Respiratory Journal demonstrated statistically significant difference in time-to-first relapse for corticosteroid use and ...
EyePoint Pharmaceuticals ( EYPT ) Reports Q3 Loss, Lags Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -12.50% and 14.79%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics, Inc. ( CCCC ) Reports Q3 Loss, Tops Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 12.50% and 158.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma to Present at Upcoming Investor Conferences - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, Oct. 31, 2024 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ATYR, a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at several upcoming ...
aTyr Pharma to Participate in September Investor Conferences
SAN DIEGO, Aug. 21, 2024 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ( Nasdaq: ATYR ) , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in ...
aTyr Pharma to Participate in September Investor Conferences - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, Aug. 21, 2024 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ATYR, a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in several upcoming ...
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update - aTyr Pharma ( NASDAQ:ATYR )
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second quarter 2024 with $81.4 million in cash, cash equivalents, restricted cash and investments.
Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying - Retractable Technologies ( AMEX:RVP )
The Dow Jones index closed lower by over 500 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading ...
aTyr Pharma ( NASDAQ:LIFE ) Coverage Initiated at StockNews.com
Equities research analysts at StockNews.com began coverage on shares of aTyr Pharma ( NASDAQ:LIFE - Get Free Report ) in a research report issued to clients and investors on Sunday. The firm set a "sell" rating on the biotechnology company's stock.
aTyr Pharma ( NASDAQ:LIFE ) Now Covered by Analysts at StockNews.com
Research analysts at StockNews.com began coverage on shares of aTyr Pharma ( NASDAQ:LIFE - Get Free Report ) in a research note issued on Saturday. The firm set a "sell" rating on the biotechnology company's stock.
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
REDWOOD CITY, Calif., June 19, 2024 ( GLOBE NEWSWIRE ) -- Jasper Therapeutics, Inc. ( Nasdaq: JSPR ) ( Jasper ) , a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit ( CD117 ) to address mast cell driven diseases such as chronic ...
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors - Jasper Therapeutics ( NASDAQ:JSPR )
REDWOOD CITY, Calif., June 19, 2024 ( GLOBE NEWSWIRE ) -- Jasper Therapeutics, Inc.
Is aTyr Pharma ( ATYR ) Outperforming Other Medical Stocks This Year?
Here is how Atyr Pharma (ATYR) and High Tide Inc. (HITI) have performed compared to their sector so far this year.
aTyr Pharma ( NASDAQ:LIFE ) Now Covered by Analysts at StockNews.com
Equities researchers at StockNews.com began coverage on shares of aTyr Pharma ( NASDAQ:LIFE - Get Free Report ) in a report issued on Friday. The brokerage set a "sell" rating on the biotechnology company's stock. Several other equities analysts have also recently issued reports on the stock.
